Abstract
Alzheimer’s disease (AD) is associated with insulin resistance and specific regional declines in cerebral metabolism. The effects of a novel mTOT modulating insulin sensitizer (MSDC-0160) were explored in non-diabetic patients with mild AD to determine whether treatment would impact glucose metabolism measured by FDG-PET in regions that decline in AD. MSDC-0160 (150 mg once daily; N=16) compared to placebo (N=13) for 12 weeks did not result in a significant difference in glucose metabolism in pre-defined regions when referenced to the pons or whole brain. However, glucose metabolism referenced to cerebellum was maintained in MSDC-0160 treated participants while it significantly declined for placebo patients in anterior and posterior cingulate, and parietal, lateral temporal, medial temporal cortices. Voxel-based analyses showed additional differences in FDG-PET related to MSDC-0160 treatment. These exploratory results suggest central effects of MSDC-0160 and provide a basis for further investigation of mTOT modulating insulin sensitizers in AD patients.
Keywords: Alzheimer’s disease, FDG-PET, insulin resistance, insulin sensitizer, mTOT modulator.
Current Alzheimer Research
Title:An Evaluation of MSDC-0160, A Prototype mTOT Modulating Insulin Sensitizer, in Patients with Mild Alzheimer's Disease
Volume: 11 Issue: 6
Author(s): Raj C. Shah, Dawn C. Matthews, Randolph D. Andrews, Ana W. Capuano, Debra A. Fleischman, James T. VanderLugt and Jerry R. Colca
Affiliation:
Keywords: Alzheimer’s disease, FDG-PET, insulin resistance, insulin sensitizer, mTOT modulator.
Abstract: Alzheimer’s disease (AD) is associated with insulin resistance and specific regional declines in cerebral metabolism. The effects of a novel mTOT modulating insulin sensitizer (MSDC-0160) were explored in non-diabetic patients with mild AD to determine whether treatment would impact glucose metabolism measured by FDG-PET in regions that decline in AD. MSDC-0160 (150 mg once daily; N=16) compared to placebo (N=13) for 12 weeks did not result in a significant difference in glucose metabolism in pre-defined regions when referenced to the pons or whole brain. However, glucose metabolism referenced to cerebellum was maintained in MSDC-0160 treated participants while it significantly declined for placebo patients in anterior and posterior cingulate, and parietal, lateral temporal, medial temporal cortices. Voxel-based analyses showed additional differences in FDG-PET related to MSDC-0160 treatment. These exploratory results suggest central effects of MSDC-0160 and provide a basis for further investigation of mTOT modulating insulin sensitizers in AD patients.
Export Options
About this article
Cite this article as:
Shah C. Raj, Matthews C. Dawn, Andrews D. Randolph, Capuano W. Ana, Fleischman A. Debra, VanderLugt T. James and Colca R. Jerry, An Evaluation of MSDC-0160, A Prototype mTOT Modulating Insulin Sensitizer, in Patients with Mild Alzheimer's Disease, Current Alzheimer Research 2014; 11 (6) . https://dx.doi.org/10.2174/1567205011666140616113406
DOI https://dx.doi.org/10.2174/1567205011666140616113406 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Alzheimer's Disease Drug Development
Alzheimer's disease is a progressive neurodegenerative disorder that affects millions of people worldwide. Despite decades of research, no cure or disease-modifying treatment is available yet. Therefore, the need for developing effective therapies to treat Alzheimer's disease is an urgent matter. This special issue aims to provide a comprehensive overview of ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cell Adhesion Molecules in Gene and Cell Therapy Approaches for Nervous System Repair
Current Gene Therapy Editorial [Hot Topic: Functions and Metabolism of Brain Nucleosides and their Metabolites (Guest Editors: Zsolt Kovacs & Arpad Dobolyi)]
Current Topics in Medicinal Chemistry Medicinal Chemistry of P2X Receptors: Agonists and Orthosteric Antagonists
Current Medicinal Chemistry Morin Inhibits Ovarian Cancer Growth through the Inhibition of NF-κB Signaling Pathway
Anti-Cancer Agents in Medicinal Chemistry Hypersensitivity Reactions to Last Generation Chimeric, Umanized and Human Recombinant Monoclonal Antibodies for Therapeutic Use
Current Pharmaceutical Design Cardioprotection by Targeting the Pool of Resident and Extracardiac Progenitors
Current Drug Targets Fluorinated Tropanes
Current Topics in Medicinal Chemistry Current Advancements in Aβ Luminescent Probes and Inhibitors of Aβ Aggregation
Current Alzheimer Research Traumatic Brain Injury and Blood-Brain Barrier Cross-Talk
CNS & Neurological Disorders - Drug Targets Genotoxicity in Alzheimers Disease: Role of Amyloid
Current Alzheimer Research Regulation of Innate Immune Responses in the Central Nervous System
CNS & Neurological Disorders - Drug Targets The Role of Autophagy on the Survival of Dopamine Neurons
Current Topics in Medicinal Chemistry Microwave Assisted Medicinal Chemistry
Mini-Reviews in Medicinal Chemistry Internet Addiction: A Brief Summary of Research and Practice
Current Psychiatry Reviews Chemical Composition and Inhibitory Effects of Hypericum brasiliense and H. connatum on Prolyl Oligopeptidase and Acetylcholinesterase Activities
Medicinal Chemistry Traditional Chinese Medicine Network Pharmacology in Cardiovascular Precision Medicine
Current Pharmaceutical Design Effects of the Capsular Polysaccharides of Cryptococcus neoformans on Phagocyte Migration and Inflammatory Mediators [General Articles]
Current Medicinal Chemistry Multi-particulate Systems: Cutting-edge Technology for Controlled Drug Delivery
Recent Patents on Drug Delivery & Formulation Optimizing Modifiable and Lifestyle-related Factors in the Prevention of Dementia Disorders with Special Reference to Alzheimer, Parkinson and Autism Diseases
Current Nutrition & Food Science PET Radioligands for the Vesicular Acetylcholine Transporter (VAChT)
Current Topics in Medicinal Chemistry